BridgeBio Pharma, Inc. (FRA:2CL)
Germany · Delayed Price · Currency is EUR 61.64
+0.22 (0.36%)
At close: Nov 28, 2025
BridgeBio Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Net Income | -797.12 | -535.76 | -643.2 | -481.18 | -562.54 | -448.72 | Upgrade |
Depreciation & Amortization | 5.37 | 6.08 | 6.49 | 6.77 | 5.84 | 1.46 | Upgrade |
Loss (Gain) From Sale of Assets | - | -178.32 | 1.24 | 6.26 | - | - | Upgrade |
Asset Writedown & Restructuring Costs | 0.27 | 0.27 | - | 12.72 | - | 4.73 | Upgrade |
Loss (Gain) From Sale of Investments | - | -8.14 | -18.31 | 8.22 | -29.91 | - | Upgrade |
Loss (Gain) on Equity Investments | 60.51 | 31.18 | - | - | - | - | Upgrade |
Stock-Based Compensation | 128.51 | 95.8 | 108.71 | 91.56 | 99.51 | 58.46 | Upgrade |
Other Operating Activities | 106.26 | 36.12 | 12.29 | -91.92 | -6.43 | -30.57 | Upgrade |
Change in Accounts Receivable | -116.04 | -2.97 | 15.33 | 15.17 | -19.75 | - | Upgrade |
Change in Accounts Payable | 5.34 | 1.51 | 2.78 | -0.35 | 2.83 | -0.74 | Upgrade |
Change in Unearned Revenue | -8.18 | 21.88 | -5.44 | 15.26 | - | - | Upgrade |
Change in Other Net Operating Assets | 54.51 | 11.63 | -7.61 | -2 | 12.52 | 15.67 | Upgrade |
Operating Cash Flow | -584.82 | -520.73 | -527.72 | -419.49 | -497.93 | -399.71 | Upgrade |
Capital Expenditures | -1.11 | -0.93 | -1.31 | -4.82 | -13.25 | -7.52 | Upgrade |
Sale of Property, Plant & Equipment | - | - | - | 10 | - | - | Upgrade |
Cash Acquisitions | - | - | - | - | 13.65 | - | Upgrade |
Divestitures | - | -0.14 | -0.5 | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | -11.69 | -7.98 | - | -1.5 | -35 | - | Upgrade |
Investment in Securities | -2.88 | 44.15 | 55.84 | 339.47 | -166.23 | -38.72 | Upgrade |
Other Investing Activities | 2.3 | 25.68 | - | 110 | - | -6.76 | Upgrade |
Investing Cash Flow | -13.37 | 60.78 | 54.03 | 453.15 | -200.83 | -52.99 | Upgrade |
Long-Term Debt Issued | - | 950 | - | - | 1,204 | 550 | Upgrade |
Long-Term Debt Repaid | - | -473.42 | - | -20.49 | -124.12 | - | Upgrade |
Net Debt Issued (Repaid) | 916 | 476.58 | - | -20.49 | 1,080 | 550 | Upgrade |
Issuance of Common Stock | 23.79 | 322.9 | 459.22 | 8.08 | 20.46 | 14.13 | Upgrade |
Repurchase of Common Stock | -56.48 | -7.53 | -6.88 | -1.56 | -204.75 | -75.71 | Upgrade |
Other Financing Activities | -47.9 | -43.5 | -0.8 | 0.84 | -158.95 | -41.23 | Upgrade |
Financing Cash Flow | 835.41 | 748.46 | 451.54 | -13.13 | 736.45 | 447.19 | Upgrade |
Net Cash Flow | 237.22 | 288.51 | -22.15 | 20.52 | 37.69 | -5.52 | Upgrade |
Free Cash Flow | -585.93 | -521.66 | -529.03 | -424.32 | -511.18 | -407.23 | Upgrade |
Free Cash Flow Margin | -165.62% | -235.08% | -5686.62% | -546.46% | -733.23% | -4936.74% | Upgrade |
Free Cash Flow Per Share | -3.08 | -2.80 | -3.25 | -2.88 | -3.54 | -3.45 | Upgrade |
Cash Interest Paid | 56.78 | 91.34 | 61.11 | 54.44 | 29.77 | 15.32 | Upgrade |
Levered Free Cash Flow | -268.52 | -288.27 | -249.07 | -285.88 | -301.13 | -250.16 | Upgrade |
Unlevered Free Cash Flow | -169.04 | -226.21 | -198.26 | -235.61 | -271.89 | -227.25 | Upgrade |
Change in Working Capital | -87.73 | 32.04 | 5.06 | 28.08 | -4.4 | 14.93 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.